Vertex Pharmaceuticals is set to acquire Crinetics for $10 billion in a move to bolster its rare-diseases pipeline. This was reported by Qazaqyia.kz citing Reuters.
The deal will strengthen Vertex's portfolio of treatments for rare diseases. The official announcement was made on July 6, 2026.